Author

D. Roychowdhury

Observed names: D F Roychowdhury, D ROYCHOWDHURY, D. F. Roychowdhury, D. ROYCHOWDHURY, D.F. Roychowdhury, ROYCHOWDHURY D., Roychowdhury DF

Institutions: University of Copenhagen, St Bartholomew's Hospital, Herlev Hospital, Aarhus University Hospital, Princess Margaret Cancer Centre

Observed institutions: University of Copenhagen, St Bartholomew's Hospital, Mayo Clinic, Eli Lilly (United States), University of California, San Francisco, Herlev Hospital, Aarhus University Hospital, Princess Margaret Cancer Centre, Cincinnati VA Medical Center, Mayo Clinic in Florida, University of Cincinnati

OpenAlex ID: A5110397240

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

2000 · H. von der Maase, S.W. Hansen, et al. · Journal of Clinical Oncology · 2,283

Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer

2003 · D.F. Roychowdhury, A. Hayden, et al. · Journal of Clinical Oncology · 119

First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study

2005 · O. Feher, P. Vodvarka, et al. · Annals of Oncology · 92

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

2023 · H. von der Maase, S.W. Hansen, et al. · Journal of Clinical Oncology · 49

Results of an analysis of cardiac function in 2,812 patients treated with lapatinib

2006 · E. A. Perez, J. A. Byrne, et al. · Journal of Clinical Oncology · 40

Antisense therapy directed to protein kinase C-alpha (affinitak, LY900003/ISIS 3521): Potential role in breast cancer

2003 · D ROYCHOWDHURY, M LAHN · Seminars in Oncology · 37

Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study

2008 · N. Altorki, M. Guarino, et al. · Journal of Clinical Oncology · 36

Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin.

1995 · D F Roychowdhury, C A Linker · PubMed · 30

Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer.

1997 · D F Roychowdhury, P Desai, et al. · PubMed · 11

Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

2006 · C.J. POOLE, T. PERREN, et al. · International Journal of Gynecological Cancer · 10

Interferon Alfa-2b and Cytarabine in Chronic Myelogenous Leukemia

1997 · T Patel, D F Roychowdhury · New England Journal of Medicine · 2

Variability in safety information in U.S. Package Inserts (USPI) for anticancer agents

2004 · D. A. Rhein, J. F. Worzalla, et al. · Journal of Clinical Oncology

Antisense therapy directed to protein kinase C-alpha (affinitak, LY900003/ISIS 3521): Potential role in breast cancer

2003 · D ROYCHOWDHURY, M LAHN · Seminars in Oncology

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.

2002 · STADLER WM, HAYDEN A., et al. · Institutional Research Information System University of Turin (University of Turin)

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

2000 · Von der Maase H, Hansen SW, et al. · Institutional Research Information System University of Turin (University of Turin)

Works count: 16

Citation count: 2,709

H-index: 10

I10-index: 10